Organization
Vertex Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Vertex Pharmaceuticals, Inc.
... and shareholders of Barracuda Networks, Inc. (NYSE:CUDA), Abraxas Petroleum Corporation (NASDAQ:AXAS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Incyte Corporation (NASDAQ:INCY), Forum Energy Technologies, Inc. (NYSE:FET), and S&P ...
... of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals is a great example of leveraging our platform to rapidly create ...
... If you want a Stock Review on SGMO, VRTX, ATHX, or AVEO then come over tohttp://dailystocktracker.com/register/and sign up for your free ...
... from birth," said David Gillen, M.D., Head of International Medical Affairs at Vertex. "This recommendation brings us closer to being able to help more people ...
... of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals is a great example of leveraging our platform to rapidly create ...
... $81.2 million reached their highest levels since the October 2016 acquisition of Vertex, and excluding Vertex, the highest level since Q 3 2015's $78.3 million. ...
... $81.2 million reached their highest levels since the October 2016 acquisition of Vertex, and excluding Vertex, the highest level since Q 3 2015's $78.3 million. ...
... BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the New England Journal of Medicine (NEJM) ...
... said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. 'We also know that many people with CF are still waiting for ...
... increase in research and development service revenue under our collaboration agreements with Vertex and Casebia. Research and development expenses were $17.8 million for the three ...
... said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. "We also know that many people with CF are still waiting for ...
... Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the New England Journal of Medicine (NEJM) ...
... 2017, a sequential increase of 0.5 percent. Adjusting for the sale of Vertex, sales increased 13.0 percent year-over-year.Earnings per diluted share was $0.16 based upon ...
... of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to ...
... newly establishing independent research programs in cystic fibrosis (CF). The program furthers Vertex's commitment to the next generation of CF researchers by expanding the existing ...
... on every one of our three new Thin-film Equipment platforms: the INTEVAC VERTEX(TM), the MATRIX(TM) and the ENERGi(TM) ion implant tool. In the third quarter, ...
... a previously disclosed goodwill impairment charge of $1.67 per diluted share for Vertex Aerospace. Diluted EPS from continuing operations for the quarter ended September 23, ...
... today reported consolidated financial results for the third quarter ended September30, 2017. Vertex also increased its total 2017 CF product revenue guidance, including revenue guidance ...
... best-performing stock in the S&P 500 this year, boasting gains of 110%. Vertex is a global biotechnology company that specializes in treatments for cystic fibrosis, ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤